Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 2
Submit an article Journal homepage
136
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Putting the brain into mantle cell lymphoma

Chiara Rusconia Division of Hematolgy and Bone Marrow Transplantation, Foundation IRCCS Istituto Nazionale Tumori, Milan, Italy;Correspondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2863-0883
ORCID Icon &
Carlo Viscob Department of Medicine, Hematology Unit, University of Verona, Verona, ItalyORCID Iconhttps://orcid.org/0000-0002-0359-767X
ORCID Icon
Pages 259-260 | Received 18 Dec 2022, Accepted 22 Dec 2022, Published online: 02 Jan 2023

References

  • Cheah CY, George A, Giné E, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the european mantle cell lymphoma network. Ann Oncol. 2013;24(8):2119–2123.
  • Ferrer A, Bosch F, Villamor N, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol. 2008;19(1):135–141.
  • McLaughlin N, Wang Y, Witzig T, et al. Central nervous system involvement by mantle cell lymphoma. Leuk Lymphoma. 2022;23:1–7.
  • Chihara D, Asano N, Ohmachi K, et al. Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). Ann Oncol. 2015;26(5):966–973.
  • Conconi A, Franceschetti S, Lobetti-Bodoni C, et al. Risk factors of central nervous system relapse in mante cell. Lymphoma. Leuk Lymphoma. 2013;54(9):1908–1914.
  • Hoster E, Dreyling M, Klapper W, European Mantle Cell Lymphoma Network, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–565.
  • Rusconi C, Cheah CY, Eyre TA, et al. Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood. 2022;140(17):1907–1916.
  • Visco C, Tisi MC, Evangelista A, Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019;185(5):940–944.
  • Visco C, Di Rocco A, Evangelista A, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from MANTLE FIRST study. Leukemia. 2021;35(3):787–795.
  • Vu K, Frank MJ. CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse. Blood Adv. 2022, https://doi.org/10.1182/bloodadvances.2022008031.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.